Arrowhead Pharmaceuticals Inc. (ARWR) Company Profile & Statistics

Arrowhead Pharmaceuticals Inc.
ARWR
(Nasdaq - US)
Open
18.75
+0.18 (+0.97%)
in:usd•As of: Nov 18, 2024 12:24 UTC -5
Open
18.75
High
18.91
Low
18.26

About Arrowhead Pharmaceuticals Inc.

CEO

Christopher Anzalone

Headquarters

177 e. colorado blvd, suite 700

pasadena, ca 91105, united states

Auditor

Rose, Snyder & Jacobs LLP

Employees

525

Share Holders

Website

www.arrowheadpharma.com

Industry

biotechnology

Sector

health technology

Company Overview

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company's proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA which are in different clinical trial phase. Arrowhead Pharmaceuticals, Inc., formerly known as Arrowhead Research Corporation, is headquartered in Pasadena, California.

Arrowhead Pharmaceuticals Inc. Statistics

Valuation Measures

Market Capitalization ²	2.33B
Enterprise Value	2.26B
Enterprise Value/EBITDA (ttm)	-4.33
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	6.80
Price to Sales (ttm)	12.70
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	50.00%
Operating Margin (ttm)	N/A
Profit Margin (ttm)	-1105.74%
Return on Equity (ttm)	-152.95%
Return on Invested Capital (ttm)	-193.55%
Return on Assets (ttm)	-63.93%

Income Statement

Revenue (ttm)	19.65M
Revenue Per Share (ttm)	0.16
Gross Profit (ttm)	19.65M
EBITDA (ttm)³	-522.88M
Net Income Avi to Common (ttm)	-538.64M
Diluted EPS (ttm)	-4.67

Share Statistics

Beta (5Y Monthly)	0.93
52-Week Change	-35.12%
S&P500 52-Week Change	29.60%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	124.32M
Dividend Yield	0.00%
Float ⁴	118.72M
% Held by Insiders	4.50%
% Held by Institutions	62.61%

Balance Sheet

Total Cash (mrq)	436.67M
Total Cash Per Share (mrq)	3.51
Total Debt (mrq)	0.00
Total Debt/Equity (mrq)	0.00%
Current Ratio (mrq)	4.65%
Quick Ratio (mrq)	4.65%
Book Value Per Share (mrq)	2.73

Cash Flow

Operating Cash Flow Per Share (ytd)	-2.62
Free Cash Flow (ytd)	-442.81M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Arrowhead Pharmaceuticals Inc.

Trade With A Regulated Broker